• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed concludes autoinjector supply deal with Novo Nordisk

September 20, 2023 By Sean Whooley

Ypsomed YpsoMate 1mL autoinjector
The YpsoMate 1mL autoinjector. [Image from Ypsomed]
Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.

Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its manufacturing capacities over the coming years.

Novo Nordisk expects to contribute a significant part of the investment for additional production infrastructure. The companies expect availability of a significant capacity of autoinjectors for Novo Nordisk “in the course of 2025.” To reduce dependences, the company plans to offer third-party manufacturers rights under a royalty scheme.

Earlier this year, the company strengthened its commitment to manufacturing in Switzerland. Ypsomed said it expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere. The company aims to substantially increase its manufacturing capacity in several steps until 2031.

Ypsomed said it sees no material financial impact from the agreement on its current 2023/24 fiscal year. It expects contributions to sales beginning in 2025/26.

“The conclusion of this contract marks an important milestone for Ypsomed,” CEO Simon Michel said. “The long-term cooperation supports our growth strategy significantly and in a sustainable way. We are pleased to enable the treatment of people with chronic conditions in a simple and safe way at home with our devices.”

Ypsomed also develops insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.

More positives for Ypsomed

The bolstering of manufacturing follows about a year of positive developments across the board at Ypsomed. Here are some of the highlights:

  • In April 2022, the company partnered with Abbott and Camdiab on automated insulin delivery.
    • The three companies launched the system in November 2022.
    • The artificial pancreas received UK authorization in April of this year.
  • In October, the company unveiled a new autoinjector
  • This past January, Ypsomed completed the sale of mail-order retailer for diabetes care DiaExpert. This sale allows the company to focus on the manufacture and sale of its own medical technologies.
  • Just this month, Ypsomed and S3 Connected Health partnered on digital offerings.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Novo Nordisk, Ypsomed

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS